AI assistant
Sending…
Ernexa Therapeutics Inc. — Director's Dealing 2021
Jul 19, 2021
35259_dirs_2021-07-19_0660c6da-b796-4177-aebb-96117cda263f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-07-15
Reporting Person: Sial Jay (N/A)
More from Ernexa Therapeutics Inc.
Major Shareholding Notification
2026
May 14
Annual Report
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Proxy Solicitation & Information Statement
2026
May 11
Interim / Quarterly Report
2026
May 11
Regulatory Filings
2026
May 4
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 31
Regulatory Filings
2026
Mar 24